Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Systems, Shamrock Structures, Trubion Pharmaceuticals, Australian Proteome Analysis Facility, LumiCyte, Genomics One, MS Vision, ABI, MDS Proteomics, Bruker BioSciences

Premium

Recent Lay-offs at Proteome Systems Will Cut Costs 30 Percent

Proteome Systems has implemented a cost-management program that is to include job cuts in its Boston and Sidney, Australia, facilities.

The exact number of jobs that will be eliminated was not immediately clear.

According to the company, the reduction in headcount, along with a decrease in space requirements, is expected to lower monthly operating costs by 30 percent and result in an annualized savings of AU$6 million ($4.7 million) once they are fully implemented early next year.

Proteome Systems also noted that John Martin, executive director of the company, is stepping down from his position. The company noted that Martin will remain a non-executive director and consultant for at least the remainder of the financial year.


Shamrock Structures to Provide Structural Proteomics Services for Trubion Pharmaceuticals

Shamrock Structures will provide integrated structural proteomics services for Trubion Pharmaceuticals, the company said last week.

Shamrock, based in Woodridge, Ill., will perform crystallization, collect synchrotron data, and determine the structure of proteins developed by Trubion in return for an upfront fee and performance-based milestone payments.

Trubion Pharmaceuticals, based in Seattle, is focused on the discovery and development of drugs to treat inflammatory diseases and cancer.

Additional terms were undisclosed.


Aussie Proteome-Analysis Facility, LumiCyte Partner In Proteomic Biomarker Discovery

The Australian Proteome Analysis Facility will partner with LumiCyte to develop LCI’s STS biochip platform technology and to accelerate proteomic biomarker discovery, the facility said last week.

Under terms of the agreement, LCI will provide access to its STS biochip platform to support APAF’s biomarker discovery-research efforts. Using mass-spectrometry techniques, APAF will provide a range of evaluation, validation and showcasing proteomic studies to characterize the performance of the STS platform.

APAF and LCI will apply collaboratively to the Australian government for funding to support the STS platform research.

Financial terms of the collaboration were not disclosed.


Genomics One Seeks to Acquire Canadian Shop’s Proteomics Assets, Assumes $175K in Debt

Genomics One has acquired from Solidarity Fund QFL a secured debt of $175,000 against Dephy Technologies, a Montreal-based proteomics company that recently filed for bankruptcy protection and ceased its activities.

Under the agreement, Genomics One will pay $175,000 and issue 20,000 common shares from its capital stock in exchange for the debt, plus accrued interest.

“Genomics One’s intent in completing this deal was to be able to acquire all the tangible and intangible assets of Dephy which include equipment, completed instruments, work in process, intellectual property, and know-how,” Suzanne Lebel, president and CEO of Genomics One, said in a statement. “Through this acquisition, Genomics One has become the only secured creditor of Dephy.”


MS Vision to Sell, Service Ionalytics’ Selectra Tech for ABI, MDS Proteomics Platform

Ionalytics and MS Vision announced last week that they have entered into a marketing agreement where MS vision will serve as Ionalytics’ European agent, providing sales and service support for the Ionalytics Selectra.

Under the agreement, MS Vision will market Ionalytics Selectra in Europe for the Applied Biosystems/MDS Sciex API 300, 365 and 3000.

According to Ionalytics, Selectra enhances mass-spectrometer performance by providing an additional dimension of ion separation. Based on FAIMS technology, the Selectra transmits a targeted subset of ions into a mass spectrometer, resulting in improved detection limits, increased selectivity and increased throughput.

Financial terms of the agreement were not disclosed.


Bruker Stock Surges 8.4 Percent One Day After CEO Gobbles Up 200,000 Shares

Shares in Bruker BioSciences were up 8.4 percent at $4.27 in mid-afternoon trading on Nov. 22 after CEO Frank Laukien spent five days buying $781,000 worth of Bruker stock.

Laukien ended the buying spree with 200,000 additional shares in his portfolio, according to the website www.insidercow.com.

Bruker has around 382 million shares outstanding and currently has a market capitalization of approximately $1.63 billion. As of Wednesday afternoon, shares were up another 47 cents, trading at $4.74.

 

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.